WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 834 - Thirty-third Report
(1993; 36 pages) View the PDF document
Table of Contents
View the documentWHO Expert Committee on Specifications for Pharmaceutical Preparations
View the document1. Introduction
Open this folder and view contents2. The international pharmacopoeia and related activities
Close this folder3. International Chemical Reference Substances and International Infrared Reference Spectra
View the document3.1. Establishment of reference substances
View the document3.2. Infrared reference spectra
View the document4. Quality control methods for medicinal plant materials
View the document5. The WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce
Open this folder and view contents6. Good manufacturing practices for pharmaceutical products
View the document7. Development of globally acceptable standards for excipients
Open this folder and view contents8. Stability of dosage forms
View the document9. Simple test methodology
View the document10. Quality assurance in pharmaceutical supply systems
Open this folder and view contents11. Pharmaceutical production in developing countries
View the document12. Training
View the documentAcknowledgements
View the documentReferences
View the documentAnnex 1 - List of available International Chemical Reference Substances1
View the documentAnnex 2 - List of available International Infrared Reference Spectra
Open this folder and view contentsAnnex 3 - Good manufacturing practices for biological products1
View the documentBack Cover

3.2. Infrared reference spectra

Further to the spectra established at the Committee’s previous meeting (3), it adopted 18 additional International Infrared Reference Spectra. Those listed in Annex 2 are now available from the WHO Collaborating Centre for Chemical Reference Substances, Stockholm, Sweden. Precise instructions for the preparation of spectra are provided with each reference spectrum. A separate document including recommendations for the preparation and use of infrared spectra in pharmaceutical analysis was provisionally adopted by the Committee subject to further consultation with the participating laboratories. Once finalized, the recommendations would accompany the reference spectra. It was noted that the general interchangeability of instruments had been confirmed during the validation exercise.

The Committee emphasized that the comparison of infrared spectra by means of either a reference spectrum or a reference substance required an appropriate level of expertise.


to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017